Contents: Groz GAT/53 Drill Chuck Arbor, Jacob Taper 3, Morse Taper Outside 5 Arrowhead Pharma Arrowhead Pharmaceuticals Inc. Reports Interim Results from Ongoing Phase 1/2 Study of ARO-C3 There were no treatment-emergent adverse events leading to drug discontinuation, dose interruptions, or premature study withdrawals in any study group. Compared with placebo, no dose-dependent or clinically […]